The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Open accessAbstract
Purpose: To determine the maximum-tolerated dose (MTD) and assess safety, pharmacokinetics, pharmacodynamics, and evidence of antitumor activity of RO4929097, a gamma secretase inhibitor of Notch signaling in patients with advanced solid malignancies. Patients and Methods: Patients received escalating doses of RO4929097 orally on two schedules: (A) 3 consecutive days per week for 2 weeks every 3 weeks; (B) 7 consecutive days every 3 weeks. To assess reversible CYP3A4 autoinduction, the expanded part of the study tested three dosing schedules: (B) as above; modified A, 3 consecutive d/wk for 3 weeks; and (C) continuous daily dosing. Positron emission tomography scans with [18 F]fluorodeoxyglucose (FDG-PET) were used to assess tumor metabolic effects. Results: Patients on schedule A (n = 58), B (n = 47), and C (n = 5; expanded cohort) received 302 cycles of RO4929097. Common grade 1 to 2 toxicities were fatigue, thrombocytopenia, fever, rash, chills, and anorexia. Transient grade 3 hypophosphatemia (dose-limiting toxicity, one patient) and grade 3 pruritus (two patients) were observed at 27 mg and 60 mg, respectively; transient grade 3 asthenia was observed on schedule A at 80 mg (one patient). Tumor responses included one partial response in a patient with colorectal adenocarcinoma with neuroendocrine features, one mixed response (stable disease) in a patient with sarcoma, and one nearly complete FDG-PET response in a patient with melanoma. Effect on CYP3A4 induction was observed. Conclusion: RO4929097 was well tolerated at 270 mg on schedule A and at 135 mg on schedule B; the safety of schedule C has not been fully evaluated. Further studies are warranted on the basis of a favorable safety profile and preliminary evidence of clinical antitumor activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Notch signalling: a simple pathway becomes complex
Bray, S. J. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2009 · Cited by 2,620
Angiogenesis: A Team Effort Coordinated by Notch
Phng, L.-K., & Gerhardt, H. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.015 · Cited by 832
The Notch signaling pathway: Transcriptional regulation at Notch target genes
Borggrefe, T., & Oswald, F. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8668-7 · Cited by 661
Notch Signaling in Development and Cancer
Bolós, V., Grego-Bessa, J., & de la Pompa, J. L. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0046 · Cited by 545
The many facets of Notch ligands
D'Souza, B., Miyamoto, A., & Weinmaster, G. (2008) · Oncogene · doi:10.1038/onc.2008.229 · Cited by 438
Rational targeting of Notch signaling in cancer
Rizzo, P., Osipo, C., Foreman, K., Golde, T., Osborne, B., & Miele, L. (2008) · Oncogene · doi:10.1038/onc.2008.226 · Cited by 395
Notch signaling regulates tumor angiogenesis by diverse mechanisms
Dufraine, J., Funahashi, Y., & Kitajewski, J. (2008) · Oncogene · doi:10.1038/onc.2008.227 · Cited by 277
NOTCH Signaling as a Novel Cancer Therapeutic Target
Miele, L., Miao, H., & Nickoloff, B. (2006) · Current Cancer Drug Targets · doi:10.2174/156800906777441771 · Cited by 201
Luistro, L., He, W., Smith, M., Packman, K., Vilenchik, M., Carvajal, D., Roberts, J., Cai, J., Berkofsky-Fessler, W., Hilton, H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1843 · Cited by 191
Self-citation
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Takebe, N., Miele, L., Harris, P. J., Jeong, W., Bando, H., Kahn, M., Yang, S. X., & Ivy, S. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.61 · Cited by 1,298
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
Krishnamurthy, N., & Kurzrock, R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.002 · Cited by 1,026
Self-citationClara, J. A., Monge, C., Yang, Y., & Takebe, N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0293-2 · Cited by 752
Therapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
Targeting Notch signaling pathway in cancer: Clinical development advances and challenges
Takebe, N., Nguyen, D., & Yang, S. X. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.005 · Cited by 413
Notch signaling: An emerging therapeutic target for cancer treatment
Yuan, X., Wu, H., Xu, H., Xiong, H., Chu, Q., Yu, S., Wu, G. S., & Wu, K. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.048 · Cited by 402
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Pont, M. J., Hill, T., Cole, G. O., Abbott, J. J., Kelliher, J., Salter, A. I., Hudecek, M., Comstock, M. L., Rajan, A., Patel, B. K. R., et al. (2019) · Blood · doi:10.1182/blood.2019000050 · Cited by 329
Targeting Notch signalling pathway of cancer stem cells
Venkatesh, V., Nataraj, R., Thangaraj, G. S., Karthikeyan, M., Gnanasekaran, A., Kaginelli, S. B., Kuppanna, G., Kallappa, C. G., & Basalingappa, K. M. (2018) · Stem Cell Investigation · doi:10.21037/sci.2018.02.02 · Cited by 275
Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0607 · Cited by 218
Self-citationStructural basis of γ-secretase inhibition and modulation by small molecule drugs
Yang, G., Zhou, R., Guo, X., Yan, C., Lei, J., & Shi, Y. (2021) · Cell · doi:10.1016/j.cell.2020.11.049 · Cited by 189
Kummar, S., O'Sullivan Coyne, G., Do, K. T., Turkbey, B., Meltzer, P. S., Polley, E., Choyke, P. L., Meehan, R., Vilimas, R., Horneffer, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.1994 · Cited by 183
Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L., & Munster, P. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy171 · Cited by 138
Self-citationvon Arx, C., Capozzi, M., López-Jiménez, E., Ottaiano, A., Tatangelo, F., Di Mauro, A., Nasti, G., Tornesello, M. L., & Tafuto, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091277 · Cited by 24
Morphologic and Functional Effects of Gamma Secretase Inhibition on Splenic Marginal Zone B Cells
de Vera Mudry, M. C., Regenass-Lechner, F., Ozmen, L., Altmann, B., Festag, M., Singer, T., Müller, L., Jacobsen, H., & Flohr, A. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/289412 · Cited by 6
“In addition, treatment with 30 mg/kg/day RO4929097 resulted in a reduction of neutralizing immunoglobulin titers of the IgG class at 7 days after vaccination (average 7.8-fold reduction), but titers recovered at later time points.”
Influential
Metadata
- Authors
- Tolcher, A. W., Messersmith, W. A., Mikulski, S. M., Papadopoulos, K. P., Kwak, E. L., Gibbon, D. G., Patnaik, A., Falchook, G. S., Dasari, A., Shapiro, G. I., Boylan, J. F., Xu, Z.-X., Wang, K., Koehler, A., Song, J., Middleton, S. A., Deutsch, J., DeMario, M., Kurzrock, R., & Wheler, J. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-07-01
- Volume
- 30
- Issue
- 19
- Pages
- 2348-2353
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2126959323
- Cited by
- 268
- References
- 9
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.